IRIS Accounts Production v24.2.0.383 08525251 director 1.9.22 31.8.23 31.8.23 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh085252512022-08-31085252512023-08-31085252512022-09-012023-08-31085252512021-08-31085252512021-09-012022-08-31085252512022-08-3108525251ns15:EnglandWales2022-09-012023-08-3108525251ns14:PoundSterling2022-09-012023-08-3108525251ns10:Director12022-09-012023-08-3108525251ns10:PrivateLimitedCompanyLtd2022-09-012023-08-3108525251ns10:SmallEntities2022-09-012023-08-3108525251ns10:AuditExempt-NoAccountantsReport2022-09-012023-08-3108525251ns10:SmallCompaniesRegimeForDirectorsReport2022-09-012023-08-3108525251ns10:SmallCompaniesRegimeForAccounts2022-09-012023-08-3108525251ns10:FullAccounts2022-09-012023-08-3108525251ns10:RegisteredOffice2022-09-012023-08-3108525251ns5:CurrentFinancialInstruments2023-08-3108525251ns5:CurrentFinancialInstruments2022-08-3108525251ns5:ShareCapital2023-08-3108525251ns5:ShareCapital2022-08-3108525251ns5:RetainedEarningsAccumulatedLosses2023-08-3108525251ns5:RetainedEarningsAccumulatedLosses2022-08-310852525112022-09-012023-08-31
REGISTERED NUMBER: 08525251 (England and Wales)















FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 AUGUST 2023

FOR

CW PHARMA CONSULTANTS LTD

CW PHARMA CONSULTANTS LTD (REGISTERED NUMBER: 08525251)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


CW PHARMA CONSULTANTS LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 31 AUGUST 2023







DIRECTOR: C B Wagstaff





REGISTERED OFFICE: 115c Milton Road
Cambridge
CB4 1XE





REGISTERED NUMBER: 08525251 (England and Wales)





ACCOUNTANTS: Prentis & Co LLP
Chartered Accountants
115c Milton Road
Cambridge
CB4 1XE

CW PHARMA CONSULTANTS LTD (REGISTERED NUMBER: 08525251)

BALANCE SHEET
31 AUGUST 2023

2023 2022
Notes £    £   
CURRENT ASSETS
Debtors 4 601,720 287,383
Cash at bank 5,078 14,502
606,798 301,885
CREDITORS
Amounts falling due within one year 5 317,291 42,740
NET CURRENT ASSETS 289,507 259,145
TOTAL ASSETS LESS CURRENT
LIABILITIES

289,507

259,145

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 289,407 259,045
SHAREHOLDERS' FUNDS 289,507 259,145

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 August 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 August 2023 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the director and authorised for issue on 21 August 2024 and were signed by:





C B Wagstaff - Director


CW PHARMA CONSULTANTS LTD (REGISTERED NUMBER: 08525251)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2023

1. STATUTORY INFORMATION

CW Pharma Consultants Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Taxation
Taxation for the year comprises current tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Pension costs and other post-retirement benefits
Payments in respect of other post-retirement benefits are charged to profit or loss in the period to which they relate.


3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2022 - 1 ) .

4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Other debtors 601,720 287,383

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade creditors 30,620 36,527
VAT 7,290 4,638
Director's current account 277,781 375
Accruals 1,600 1,200
317,291 42,740

CW PHARMA CONSULTANTS LTD (REGISTERED NUMBER: 08525251)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 AUGUST 2023

6. RELATED PARTY DISCLOSURES

Aston Pharmaceuticals Limited
As at the balance sheet date, the company was owed £155,822 (2022 - £141,656) by Aston Pharmaceuticals Limited. There are no fixed repayment terms in place. Interest of £14,166 (2022 - £5,167) has been charged on the outstanding amount.

Meta Healthcare Limited
As at the balance sheet date, the company was owed £351,583 (2022 - £104,031) by Meta Healthcare Limited. There are no fixed repayment terms in place. Interest of £14,552 (2022 - £8,031) has been charged on the outstanding amount.

Vantage Pharmaceuticals Limited
As at the balance sheet date, the company was owed £94,315 (2022 - £41,696) by Vantage Pharmaceuticals Limited. There are no fixed repayment terms in place. Interest of £7,619 (2022 - £1,696) has been charged on the outstanding amount.

7. ULTIMATE CONTROLLING PARTY

The ultimate controlling party is Hualel Holdings Limited by virtue of its 100% ownership of the ordinary share capital . Hualel Holdings Limited is under the control of C B Wagstaff.